Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy

Published:2017-07-16 Issue:6 Volume:120 Page:815-821
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

De Bruycker Aurélie¹,Lambert Bieke²,Claeys Tom³,Delrue Louke⁴,Mbah Chamberlain¹,De Meerleer Gert¹,Villeirs Geert²,De Vos Filip⁵,De Man Kathia⁶,Decaestecker Karel³,Fonteyne Valérie¹,Lumen Nicolaas³,Ameye Filip⁷,Billiet Ignace⁸,Joniau Steven⁹,Vanhaverbeke Friedl¹⁰,Duthoy Wim¹¹,Ost Piet¹

Affiliation:

1. Department of Radiation Oncology and Experimental Cancer Research; Ghent University; Gent Belgium

2. Department of Radiology and Nuclear Medicine; Ghent University; Gent Belgium

3. Department of Urology; Ghent University Hospital; Gent Belgium

4. Department of Radiology; Ghent University Hospital; Gent Belgium

5. Department of Radiopharmacy; Ghent University; Gent Belgium

6. Department of Nuclear Medicine; Ghent University Hospital; Gent Belgium

7. Department of Urology; AZ Maria-Middelares; Ghent Belgium

8. Department of Urology; AZ Groeninge; Kortrijk Belgium

9. Department of Urology; Catholic University; Leuven Belgium

10. Department of Urology; AZ Nikolaas; Sint-Niklaas Belgium

11. Department of Radiotherapy; AZ Sint Lucas; Ghent Belgium

Funder

‘Kom op tegen Kanker’

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.13938/fullpdf

Reference26 articles.

1. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial;James;Lancet,2016

2. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015

3. Natural history of progression after PSA elevation following radical prostatectomy;Pound;JAMA,1999

4. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer;Ost;Prostate,2014

5. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy;Schweizer;Ann Oncol,2013

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of Tumor Characteristics and Time to Metastatic Disease on Oncological Outcomes in Metachronous Metastatic Prostate Cancer Patients;Clinical Genitourinary Cancer;2024-10

2. Resting-state networks and anosognosia in Alzheimer’s disease;Frontiers in Aging Neuroscience;2024-06-05

3. Rectal Spacer Reduces Gastrointestinal Side Effects of Radiation Post Radical Prostatectomy;Société Internationale d’Urologie Journal;2024-04-16

4. PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial;European Urology Oncology;2023-10

5. Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis;Acta Oncologica;2023-08-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3